Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.

Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, Jiang G, Lin H, Zhang X, Zuo L, He Q, Fu P, Li X, Ni D, Hemmerich S, Liu C, Szczech L, Besarab A, Neff TB, Peony Yu KH, Valone FH.

Nephrol Dial Transplant. 2017 Aug 1;32(8):1373-1386. doi: 10.1093/ndt/gfx011.

2.

Outcomes and effectiveness of posterior occipitocervical fusion for suboccipital spinal metastases.

Luksanapruksa P, Buchowski JM, Wright NM, Valone FH 3rd, Peters C, Bumpass DB.

J Neurosurg Spine. 2017 May;26(5):554-559. doi: 10.3171/2016.10.SPINE16392. Epub 2017 Feb 24.

PMID:
28291404
3.

Current trends in rotator cuff repair: surgical technique, setting, and cost.

Iyengar JJ, Samagh SP, Schairer W, Singh G, Valone FH 3rd, Feeley BT.

Arthroscopy. 2014 Mar;30(3):284-8. doi: 10.1016/j.arthro.2013.11.018. Epub 2014 Jan 24.

PMID:
24468325
4.

Trends in hip arthroscopy utilization in the United States.

Bozic KJ, Chan V, Valone FH 3rd, Feeley BT, Vail TP.

J Arthroplasty. 2013 Sep;28(8 Suppl):140-3. doi: 10.1016/j.arth.2013.02.039. Epub 2013 Aug 1.

PMID:
23916639
5.

Stereotactic lesions for the treatment of psychiatric disorders.

Leiphart JW, Valone FH 3rd.

J Neurosurg. 2010 Dec;113(6):1204-11. doi: 10.3171/2010.5.JNS091277. Epub 2010 Jun 18. Review.

PMID:
20560726
6.

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM.

J Clin Oncol. 2006 Jul 1;24(19):3089-94.

PMID:
16809734
7.

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S.

Prostate. 2004 Aug 1;60(3):197-204.

PMID:
15176049
8.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2142-8. Review.

9.

Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer.

Laport GG, Valone FH, Zimmerman TM, Grinblatt DL, Van Vlasselaer P, Still BJ, Williams SF.

Cytotherapy. 2000;2(3):179-85.

PMID:
12042040
10.

Dendritic cell-based treatment of cancer: closing in on a cellular therapy.

Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R.

Cancer J. 2001 Nov-Dec;7 Suppl 2:S53-61.

PMID:
11777265
12.

Bispecific Antibody MDX-210 for Treatment of Advanced Ovarian and Breast Cancer.

Kaufman PA, Wallace PK, Valone FH, Wells WA, Memoli VA, Ernstoff MS.

Methods Mol Med. 2001;39:793-806. doi: 10.1385/1-59259-071-3:793.

PMID:
21340841
13.

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH.

J Clin Oncol. 2000 Dec 1;18(23):3894-903.

PMID:
11099318
14.

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlović S.

Clin Cancer Res. 2000 Jun;6(6):2175-82.

15.

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.

Graziano SL, Valone FH, Herndon JE 2nd, Crawford J, Richards F 2nd, Rege VB, Clamon G, Green MR.

Lung Cancer. 1996 Jun;14(2-3):315-29.

PMID:
8794413
16.

Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.

Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Ernstoff MS, Wells W, Barth R, Deo Y, Fisher J, et al.

J Hematother. 1995 Oct;4(5):471-5.

PMID:
8581387
17.

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, et al.

J Clin Oncol. 1995 Sep;13(9):2281-92.

PMID:
7545221
19.

Soluble normal and mutated DNA sequences from single-copy genes in human blood.

Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL.

Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):67-71.

20.

Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies.

Valone FH, Gandara DR, Luce JA, Wall S, Perez EA, Braham N, George M, Letvak L.

Cancer Chemother Pharmacol. 1993;32(3):215-20.

PMID:
8500227
21.
22.
23.

Tumor necrosis factor release by human monocytes stimulated with platelet-activating factor.

Ruis NM, Rose JK, Valone FH.

Lipids. 1991 Dec;26(12):1060-4.

PMID:
1668105
24.

Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.

Valone FH, Gandara DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR, Luce J, Paradise C.

J Immunother (1991). 1991 Jun;10(3):207-13.

PMID:
1651106
25.

Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study.

Gandara DR, Valone FH, Perez EA, Deisseroth AB, Roach M 3rd, Ahn DK, Phillips T.

Int J Radiat Oncol Biol Phys. 1991 May;20(5):1047-52.

PMID:
1850719
26.
27.

Synthesis of platelet activating factor by ocular tissue from inflamed eyes.

Rosenbaum JT, Boney RS, Samples JR, Valone FH.

Arch Ophthalmol. 1991 Mar;109(3):410-3.

PMID:
2003804
28.

Platelet-activating factor stimulates expression of IL-1 beta mRNA in THP-1 cells.

Barthelson RA, Valone FH.

Lipids. 1991 Mar;26(3):257-60.

PMID:
1710753
29.

Binding of viridans group streptococci to human platelets: a quantitative analysis.

Sullam PM, Payan DG, Dazin PF, Valone FH.

Infect Immun. 1990 Nov;58(11):3802-6.

30.
31.

Synergistic increases in IL-1 synthesis by the human monocytic cell line THP-1 treated with PAF and endotoxin.

Barthelson RA, Potter T, Valone FH.

Cell Immunol. 1990 Jan;125(1):142-50.

PMID:
2293896
33.

Anaphylactoid reactions to vascular graft material presenting with vasodilation and subsequent disseminated intravascular coagulation.

Roizen MF, Rodgers GM, Valone FH, Lampe GH, Benefiel DJ, Gelman S, Rapp J, Weiler JM, Ota M, Shuman MA, et al.

Anesthesiology. 1989 Sep;71(3):331-8.

PMID:
2528305
34.

Allergy and immunology: platelet-activating factor.

Valone FH.

West J Med. 1989 Mar;150(3):334.

35.

Late appearance of phospholipid platelet-activating factor and leukotriene B4 in human skin after repeated antigen challenge.

Shalit M, Valone FH, Atkins PC, Ratnoff WD, Goetzl EJ, Zweiman B.

J Allergy Clin Immunol. 1989 Mar;83(3):691-6.

PMID:
2538500
36.

Mechanisms for biphasic or persistent immunologic reactions induced by platelet-activating factor.

Valone FH, Barthelson R, Ruis NM.

Prog Clin Biol Res. 1989;297:71-80; discussion 80-1. Review. No abstract available.

PMID:
2685826
37.
38.

Role of immunoglobulin G in platelet aggregation by viridans group streptococci.

Sullam PM, Jarvis GA, Valone FH.

Infect Immun. 1988 Nov;56(11):2907-11.

39.

Enhanced human monocyte cytotoxicity by platelet-activating factor.

Valone FH, Philip R, Debs RJ.

Immunology. 1988 Aug;64(4):715-8.

40.
41.
42.

Distinctive patterns of release of neuroendocrine peptides after nasal challenge of allergic subjects with ryegrass antigen.

Walker KB, Serwonska MH, Valone FH, Harkonen WS, Frick OL, Scriven KH, Ratnoff WD, Browning JG, Payan DG, Goetzl EJ.

J Clin Immunol. 1988 Mar;8(2):108-13.

PMID:
2453530
43.

Technetium-99m labeled 50H.19 antibody fragments: interaction of the antibody with platelets.

Valone FH, Stricker RB, Zamora PO, Shah VO, Mann PL.

Int J Rad Appl Instrum B. 1988;15(4):439-50.

PMID:
3255740
44.
45.

Interrelationships among platelet-activating factor binding and metabolism and induction of platelet activation.

Valone FH.

Prog Clin Biol Res. 1988;283:319-40. Review. No abstract available.

PMID:
2850575
47.

Mechanisms of platelet aggregation by viridans group streptococci.

Sullam PM, Valone FH, Mills J.

Infect Immun. 1987 Aug;55(8):1743-50. Erratum in: Infect Immun 1987 Nov;55(11):2864.

48.
49.

Supplemental Content

Loading ...
Support Center